Zhejiang Hisoar Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of active pharmaceutical in...
REG - GSK PLC - Hansoh positive 2nd Phase III results for Riz-Rez
HISOAR released its performance for the first half of the year, with a net profit attributable to the parent company of 14.0937 million yuan, a decrease of 63.01%
A-share weight loss drug concept stocks continued to weaken in the afternoon, Menovo hit the limit down, Medicilon and Kanion Pharmaceutical fell over 7%, SDKX and HISOAR had the largest declines
HISOAR: First repurchase of 0.05% of the company's shares
HISOAR: The market holds an overall optimistic attitude towards the price recovery of Peinan products
Innovative drugs and CRO concept stocks strengthen again, Sunshine Guojian Pharmaceutical rises over 10%